News and Events

Now Available: Dataset for “Development of a Definition of Postacute Sequelae of SARS-CoV-2 Infection”

Authorized researchers may request access to the dataset, which contains more than 3.3 million de-identified data entries and a Data Dictionary.

Changes in the body provide clues for the development of Long COVID

A research team that includes RECOVER researchers found changes in the immune systems of people with Long COVID.

RECOVER-NEURO enrolls first participant in trial

RECOVER-NEURO will enroll 315 people and test several different treatments for Long COVID patients who have difficulty focusing, thinking clearly, and remembering things.

NIH launches long COVID clinical trials through RECOVER Initiative, opening enrollment

Initially, RECOVER will test at least four potential treatments for Long COVID, with test of seven more treatments expected in the coming months.

RECOVER-VITAL enrolls first participant in trial

RECOVER-VITAL will enroll 900 people over the next six months and seek to understand whether taking Paxlovid, an antiviral drug, can improve Long COVID symptoms caused by viral persistence.

R3 Seminar Recap: RECOVER in Action: Disparities and Environmental Risk Factors in PASC, EHR Insights

During the July 11th RECOVER Research Review (R3) Seminar, presenters discussed the disparities and environmental risk factors in PASC using EHR Insights. This seminar explored racial and ethnic disparities as well as community-level environmental factors in PASC among adults.

R3 Seminar Recap: RECOVER in Action: Characterization of PASC Among Adults, Cohort Insights

During the June 13th RECOVER Research Review (R3) Seminar, RECOVER researchers described a symptom-based approach for defining long COVID in adults from a study published in JAMA. This presentation is based upon some early findings from the RECOVER Adult Observational Cohort study.

RECOVER Research Q&A: RECOVER “First Look” Adult Cohort Study

Find answers to some of the most frequently asked questions (FAQs) about the first findings from RECOVER's research on Long COVID in adults.